Immunomodulatory approaches to the therapy of AIDS

Clinical Immunotherapeutics

Volumn 6, Issue 1, 1996, Pages 39-53

  Fahey, John L ^a   Mitsuyasu, Ronald ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIGEN P24; CD4 ANTIGEN; GLUTATHIONE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MEGESTROL; PENTOXIFYLLINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RECOMBINANT SOMATOMEDIN C; TETRAHYDROCANNABINOL; THALIDOMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIOXIDANT ACTIVITY; DRUG MECHANISM; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW;

EID: 0029746496     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259351     Document Type: Review

References (61)

1. Fauci AS, Multifactorial nature of human immunodeficiency virus disease: implication for therapy. Science 1993; 262: 1011-8
2. Plata F, Dadaglio G. Chenciner N. et al. Cytotoxic T lymphocytes in HIV-induced disease: implications lor therapy and vaccination. Immunodefic Rev 1989; 1: 227-46
3. Fahey JL, Prince H. Weaver MM. et al. Quantitative changes in Th and Ts lymphocyte subsets that distinguish AIDS syndrome from other immune subset disorders. Am J Med 19X4. 76: 95-100
4. Wei X, Gho.sh SK. Taylor ME, et al. Viral dynamics in human immunodeficiency virus type I infection. Nature 1995; 373: 117-22
5. Ho D, Neuman AU, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995:373: 123-6
6. Hofmann B, Lindhardt BO. Gerstoft J. et al. The lymphocyte transformation response to pokeweed mitogen is a highly predictive parameter for the development of AIDS. BMJ 19X7: 295: 293-6
7. Fahey JL, Taylor JMG. Detels R. et al. The prognostic value of cellular and sérologie markers in infection with HIV l. N Engl JMed 1990:322: 166-72
8. Moss AR, Bacchetti P. Osmond D. et al. Seropositivily for HIV and the development of AIDS or AIDS related conditions. BMJ 1988:296:745-50
9. Giorgi JV, Liu Z. Hultin L. et al. Elevated levels of CD3X+ CD8+ T cells in HIV infection add to the prognostic value of low CD4 T cell levels. J Acq Immune Defic Syndr 1993; 6: 904-12
10. Fan J, Bass HZ, Fahey JL. Elevated IFNY and decreased IL-2 gene expression are associated with HIV infection. J Immunol 199.3; 151: 5031-40
11. Breen EC, Reïai AR. Nakajima K. et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990; 144: 480-6
12. Romagnani S, Human Thl and Th2 subsets: doubt no more. Immunol Today 1991: II: 256-9
13. Clerici M, Shearer GM. The T helper cell shift in AIDS: significance for pharmacotherapy. Clin Immunother 1995; 3 (2): 95-101
14. Folks TM, Clouse KA. Justement J. et al. Tumor necrosis lactor-a induces expression of HIV in chronically infected T cell clone. Proc Natl Acad Sei USA 1989; 86: 2365 8
15. Miles SA, Martine-4-Maza O. Rezai A. et al. Oncostatin M as a potent mitogen for AIDS Kaposi's sarcoma cells. Science 1992: 255: 1432-4
16. Staal FJ, Ela SW, Roederer M. et al. Glutathione deficiency and human immunodeficiency virus infection. Lancet 1992: 339 (879X1:909-12
17. Hofmann B, Nishanian P. Nguyen T. et al. Restoration of T cell function in HIV infection by reduction ol intraeellular cAMP levels with adenosine analogues. AIDS 1993; 7: 659-64
18. Amiesen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991; 12: 102-4
19. Clerici M, Stocks NI, Zajoc RA, et al, Detection of three distinct patterns of T helper dysfunction in asymptomatic HIV seropositive patients. J Clin Invest 1989; 84: 1892-9
20. Huber C, Batchelor JR, Fuchs D, et al. Immune responseassociated production of neopterin. J Exp Med 1984; 160: 310-6
21. Hofmann B, Bass H, Nishanian P, et al. Different lymphoid cell populations produce varied levels of neopterin, beta-2 microglobulin and sIL-2R when stimulated by 1L-2, IFN-y and TNF-a. Clin Exp Immunol 1992; 88: 548-54
22. Hofmann B, Nishanian P, Fahey JL, et al, Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: distinctive parameters of HIV-induced change. Clin Immunol Immunopathol 1991; 61: 212-24
23. Bass HZ, Nishanian P, Hardy WD, et al, Immune change in HIV infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. Clin Immunol Immunopathol 1992; 64: 63-70
24. Kohlberg J, Shen LP, Urdea M, et al, Quantitation of cellular mRNA for TNFa, IL-6, IL-2 and IFNy in HIV positive patients using bDNA assays. Proceedings of the First International Symposium on HIV and Cytokines; 1995 Mar 15-17: Rheims. In press
25. Nishanian P, Huskins KR, Stehn S, et al, A simple method for improved assay demonstrate that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 1990; 162: 21-8
26. Miles SA, Balden E, Magpanly L, et al, Rapid sérologie testing with immune-complex-dissociated HIV p24 antigen for early detection of HIV infection in neonates. N Engl J Med 1993; 328: 297-302
27. Coombs RW, Collier AC, Allain JP, et al, Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989; 321: 1626-31
28. Hammer S, Crumpacker C, D' Aquila R, et al, Use of virologie assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS clinical trials group virology committee. J Clin Microbiol 1994; 31: 2557-64
29. Urdea MS, Wilber JL, Yeghiazarian T, et al, Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS 1993; 7 Suppl. 2:811-4
30. Hsiang JL, Myers LE, Hollinger BY, et al, Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994; 170: 553-62
31. Mohri H, Singh MK, Ching WTW, et al, Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Nail Acad Sei USA 1993:90:25-9
32. Sheppard HW, Ascher MS, McRae B, et al, The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J AIDS 1991; 4: 704-12
33. Wrin T, Crawford L, Sawyer L. et al. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J AIDS 1994; 7: 211-9
34. Krown SE, Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin North Am 1991; 5: 311-22
35. Fahey JL, Taylor JMG, Detels R, A better index of HIV disease than just CD4 T cell levels [abstract]. Program and abstracts: IXth International Conference on AIDS; 1993 Jun 6-11; Berlin, abstr. no. WS-B02-5
36. Jacobson JM, Colman N, Ostorw NA, Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis 1993; 168: 298-305
37. Stiehm ER, Mofenson L, Zolla-Pasner S, et al, Summary of the workshop on passive immunotherapy in the prevention and treatment of HIV infection. Clin Immunol Immunopathol 1995:75(1): 1-10
38. Hinkula J, Brait G, Gilljam G, et al, Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J Acq Immune Defic Syndr 1994; 7: 940-51
39. Walker CM, Moody DJ, Stiles DP, et al, CD8 lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234: 1563-5
40. Ho M, Armstrong J, McMahon D, et al, A phase I study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood 1993; 81:2093-101
41. Lane HC, Zunich KM, Wilson W, el al, Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 1990; 113: 512-9
42. Redfield RR, Birx DL, Ketter N, et al, A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gpl60 in patients with early human immunodeficiency virus infection. N Engl J Med 1991 ; 324: 1677-84
43. Turner JL, Trauger RJ, Daigle AE, et al, HIV-1 immunogen induction of Hl V-1 specific delayed-type hypersensitivity. AIDS 1994; 8: 1429-35
44. Lane HC, Siegel JP, Rook AH, et al, Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Response Mod 1984; 3: 512-6
45. Teppler H, Kaplan G, Smith K, et al, Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291-8
46. Kovacs JA, Baseler M, Dewar RJ, et al, Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl JMed 1995:332:567-75
47. Clerici M, Lucey DR, Berzofsky JA, et al, Interleukin-12: important cytokine in HIV-1 immunopathogenesis. Science 1993;262:1721-4
48. Giri JG, Andeson DM, Kumaki S, et al, IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol 1995; 57: 763-6
49. Lane HC, Davey Jr RT, Sherwin SA, et al, A phase I trial of recombinant human interferon-yin patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol 1989; 9: 351-61
50. Romagnani S, del Prête G, Manetti R, et al, Role of TH1/TH2 cytokines in HIV infection. Immunol Rev 1994; 140: 73-92
51. Dezube BJ, Pardee AB, Chapman B, et al, Pentoxifylline decreases tumor necrosis factor expression and serum triglycérides in people with AIDS. J Acq Immune Defic Syndr 1993; 6: 787-94
52. Paterson DL, Georghiou PR, Allworth AM, et al, Thalidomide as treatment of refractory aphthous ulcération related to human immunodeficiency virus infection. Clin Infect Dis 1995; 20: 250-4
53. Lederman M, Georges D, Borum P, et al, L-2-Oxothiazolidinecarboxylate (procysteine) inhibits HIV-1 expression but not
54. interleukin-2 secretion [abstract], Program and abstracts: IXth International Conference on AIDS: 1993 Jun 6-11: Berlin, abstr. no. PO-A28-068I
55. de Quay B, Malinverni R. Lauterburg B. Glutathione depletion in HIV-intected patients: role of cysteine deficiency and effect of oral N-acetylcysteine, AIDS 1992: 6 (8): 815-9
56. Nguyen BY, Clerici M, Yarchoan R. et al. Immunologie effects of human insulin-like growth factor and recombinant human growth hormone in HIV-intected patients. AIDS Res Hum Retrovir 1995: II Suppl. I:SI64
57. Schambelan M, LaMarca A, Mulligan K. et al. Growth hormone therapy for AIDS wasting [abstract]. Proceedings of the I Oth International Conference on AIDS: 1994 Aug 7-12: Yokohama. 2: 35
58. Rohrbaugh ML, McGowan JJ. Gene transfer for therapy and prophylaxis of HIV-1 infection. Ann NY Acad Sei 1993 Jun 23: 685: 697-712
59. Stein DS, Timpone JG. Gradon JD. et al. Immune-based therapeuties: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus infected individual. Clin Infect Dis 1993; 17: 749-71.
60. Fahey JL, Schooley R. Status of immune-based therapies in HIV infection and AIDS. Clin Exp Immunol 1992: 88: 1-5
61. Lederman MM, Host-directed and immune-based therapies for human immunodeficiency virus infection. Ann Intern Med 1995; 122: 218-22